Phase I/II trial of DPX 0907 cancer vaccine in patients with breast and ovarian cancers
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 03 May 2018
At a glance
- Drugs DPX 0907 (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 20 Apr 2015 Status changed from planning to withdrawn prior to enrolment, according to an Immunovaccine media release.
- 20 Apr 2015 According to an Immunovaccine media release, this trial will no longer proceed due to unforeseen extended delays at the clinical site.